Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Rudakova AV, Tatarskii BA. Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation. Kardiologiia 2014; 54(7): 43-52 Indexing Status Subject indexing assigned by NLM MeSH Administration, Oral; Anticoagulants /economics /pharmacology; Atrial Fibrillation /blood /complications /drug therapy /economics /epidemiology; Benzimidazoles /economics /pharmacology; Blood Coagulation /drug effects; Cost-Benefit Analysis /statistics & Dabigatran; Drug Monitoring; Hemorrhage /chemically induced /prevention & Humans; Models, Statistical; Morpholines /economics /pharmacology; Myocardial Infarction /blood /etiology /mortality /prevention & Prognosis; Pyrazoles /economics /pharmacology; Pyridones /economics /pharmacology; Risk Factors; Rivaroxaban; Russia /epidemiology; Stroke /blood /etiology /mortality /prevention & Thiophenes /economics /pharmacology; Warfarin /economics /pharmacology; beta-Alanine /analogs & control; control; control; derivatives /economics /pharmacology; numerical data AccessionNumber 22014039544 Date bibliographic record published 16/12/2014 |